BRCA2 and cancer: This highlighted the need for more resources for carriers, particularly for genes other than BRCA1 and BRCA2. The ptDA we are co-designing is tailored based on personal characteristics to present risk estimates and relevant options spanning from targeted treatment of cancer to primary prevention of future cancers.